(FM) Oncología
Departamento académico
Gustave Roussy Cancer Campus
Villejuif, FranciaPublicaciones en colaboración con investigadores/as de Gustave Roussy Cancer Campus (64)
2024
-
An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer
Molecular Cancer, Vol. 23, Núm. 1
-
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials
Nature Communications, Vol. 15, Núm. 1
-
ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 35, Núm. 3, pp. 248-266
-
Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors
Clinical Cancer Research, Vol. 30, Núm. 8, pp. 1630-1641
-
Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer
Bulletin du Cancer, Vol. 111, Núm. 3, pp. 277-284
2023
-
Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆
Annals of Oncology, Vol. 34, Núm. 10, pp. 833-848
-
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial
Annals of Oncology, Vol. 34, Núm. 8, pp. 681-692
-
Overall Survival with Maintenance Olaparib at a 7-Year Follow-Up in Patients with Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
Journal of Clinical Oncology, Vol. 41, Núm. 3, pp. 609-617
-
Overall Survival with Maintenance Olaparib at a 7-Year Follow-up in Patients with Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
Obstetrical and Gynecological Survey
-
Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Clinical Cancer Research, Vol. 29, Núm. 21, pp. 4419-4429
-
Variation in response rates to isolated limb perfusion in different soft-tissue tumour subtypes: an international multi-centre study
European Journal of Cancer, Vol. 190
2022
-
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade
Journal for immunotherapy of cancer, Vol. 10, Núm. 5
-
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study
The Lancet Oncology, Vol. 23, Núm. 2, pp. 248-258
-
Genome-driven medicine for patients with recurrent glioma enrolled in early phase trials
European Journal of Cancer, Vol. 163, pp. 98-107
-
Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study
ESMO Open, Vol. 7, Núm. 5
-
Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial
European Journal of Cancer, Vol. 174, pp. 221-231
-
Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial
Journal for immunotherapy of cancer, Vol. 10, Núm. 8
-
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
Annals of Oncology, Vol. 33, Núm. 12, pp. 1250-1268
2021
-
Association of the lung immune prognostic index with immunotherapy outcomes in mismatch repair deficient tumors
Cancers, Vol. 13, Núm. 15
-
Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis
European Journal of Cancer, Vol. 152, pp. 68-77